Evaluation of PDZD11 in hepatocellular carcinoma: prognostic value and diagnostic potential in combination with AFP
PDZD11 is more sensitive than AFP in assessing HCC prognosis. In conclusion, PDZD11 is a promising supplementary biomarker for HCC diagnosis and prognosis alongside AFP.
Authors
- Weizhen Zhang (ORCID: https://orcid.org/0000-0001-8791-2798)
- Yiyun Ni (ORCID: https://orcid.org/0000-0002-4337-6353)
- Huihui Fan (ORCID: https://orcid.org/0000-0003-4233-5389)
- Yang Zheng (ORCID: https://orcid.org/0000-0002-4304-7912)
- Yilin Pang (ORCID: https://orcid.org/0000-0003-4920-2423)
- Shengwen Shi (ORCID: https://orcid.org/0009-0006-9313-8229)
- Qingsong Lv
- Yaling Tian
- Bin Liu (ORCID: https://orcid.org/0009-0001-0840-7329)
Institutions
- Wenzhou Medical University (CN)
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.3389/fonc.2025.1533865
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32